Photosensitivity disease

Summary

Photosensitivity disease (MONDO:0006597) is a disease and 4 clinical trials. Top therapeutic interventions include diclofenac. A subtype of radiodermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	photosensitivity disease
Mondo ID	MONDO:0006597
EFO	EFO:1000752
MeSH	D010787
DOID	DOID:3159
SNOMED CT	22649008
UMLS	C0031762
MedGen	19281
Is cancer (heuristic)	no

Also known as: disorder, photosensitivity · disorders, photosensitivity · photodermatitides · photodermatitis · photodermatosis · photosensitivity disorder · photosensitization

Disease family

This is a subtype of radiodermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › radiodermatitis › photosensitivity disease

Subtypes (4): skin sensitivity to sun, photoallergic dermatitis, phototoxic dermatitis, polymorphic light eruption

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00204542	PHASE4	COMPLETED	Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
NCT02904564	PHASE4	UNKNOWN	Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation
NCT01491620	Not specified	COMPLETED	Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
NCT01776983	Not specified	COMPLETED	Skin Aging in Renal Transplant Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DICLOFENAC	4	1